NCT03259529View on ClinicalTrials.gov

Safety and Efficacy of Bendamustine, Gemcitabine, Rituximab, Nivolumab (BeGeRN) in Patients With r/r DLBCL

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

March 27, 2017

Primary Completion Date

January 27, 2020

Study Completion Date

January 27, 2020

Conditions
Diffuse Large B Cell Lymphoma
Interventions
DRUG

Bendamustine hydrochloride

70 mg/m2 by intravenous (IV) infusion for up to 2 cycles

DRUG

Gemcitabine 500 mg

500 mg/m2 by intravenous (IV) infusion on day 1,8,15 for up to 2 cycles

DRUG

Gemcitabine 700 mg

700 mg/m2 by intravenous (IV) infusion on day 1,8,15 for up to 2 cycles

DRUG

Gemcitabine 1000 mg

1000 mg/m2 by intravenous (IV) infusion on day 1,8,15 for up to 2 cycles

DRUG

Nivolumab

1 mg/kg by intravenous (IV) infusion on day 1,15 for up to 2 cycles

DRUG

Rituximab

375 mg/m2 by intravenous (IV) infusion on day 0 for up to 2 cycles

Trial Locations (1)

197089

First Pavlov State Medical University of St. Petersburg, Saint Petersburg

All Listed Sponsors
lead

St. Petersburg State Pavlov Medical University

OTHER

NCT03259529 - Safety and Efficacy of Bendamustine, Gemcitabine, Rituximab, Nivolumab (BeGeRN) in Patients With r/r DLBCL | Biotech Hunter | Biotech Hunter